A Phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy

Project: Research

Project Description

NMA HREC Reference Number: HREC/47608/MonH-2018-157242(v1)
NMA SSA Reference Number: SSA/47608/MonH-2019-170836(v1)
Monash Health Ref: RES-18-0000-710A
StatusActive
Effective start/end date30/04/19 → 29/04/24
View all
View less

Keywords

  • clinical trial
  • immunotherapy
  • treatment efficacy
  • phase 2 trial
  • renal cell carcinoma
  • clinical trial
  • immunotherapy
  • treatment efficacy
  • phase 2 trial
  • renal cell carcinoma
  • clinical trial
  • immunotherapy
  • treatment efficacy
  • phase 2 trial
  • renal cell carcinoma